ACADIA Pharmaceuticals Signals Confident Path After Q1 Call

ACADIA Pharmaceuticals Inc. ((ACAD)) has held its Q1 earnings call. Read on for the main highlights of the call.

ACADIA Pharmaceuticals’ latest earnings call struck an overall upbeat tone as management balanced strong commercial momentum with manageable headwinds. Executives highlighted double‑digit adjusted revenue growth, accelerating adoption of key products and a well‑funded pipeline, while acknowledging higher spending, regulatory uncertainty in Europe and leadership transition risks as largely temporary or strategic.

Solid Top-Line Revenue Growth

ACADIA reported Q1 2026 revenue of $268 million, translating to an adjusted year‑over‑year increase of 11% and underscoring durable demand across its neurology portfolio. Management emphasized that this growth came despite some timing-related headwinds in NUPLAZID refills, suggesting an even stronger underlying trajectory for the business.

DAYBUE Strong Momentum and New Formulation Launch

DAYBUE delivered net sales of $101 million in Q1, up 20% year over year, driven by continued uptake in Rett syndrome patients. The company highlighted encouraging early results from the new DAYBUE STIX formulation, with more than 250 prescriptions, a meaningful share of treatment‑naive or restarting patients and caregiver satisfaction above 80%.

NUPLAZID Durable Franchise and Demand Growth

NUPLAZID net sales reached $167 million in Q1, reflecting adjusted growth of 6% year over year, supported by roughly 11% growth in physician referrals and 8% demand growth. ACADIA also completed a roughly 30% expansion of its customer‑facing sales force and reiterated its goal of driving NUPLAZID toward approximately $1 billion in annual sales by 2028.

Pipeline Catalysts and Development Progress

Management spotlighted a series of near‑term catalysts, including Phase II top‑line data for remlifanserin expected between August and October 2026 and Phase III data for trofinetide in Japan expected between September and November 2026. The company now counts four molecules aimed at large markets with an estimated combined peak sales potential of about $11 billion, roughly $4 billion of which is attributed to remlifanserin.

Financial Position and Guidance Reaffirmed

ACADIA ended the quarter with $851 million in cash, up from $820 million previously, bolstering its ability to fund commercial and R&D plans without near‑term financing pressure. The company reaffirmed its 2026 net sales guidance of $1.22 billion to $1.28 billion, while noting that R&D expenses eased slightly to $76.9 million and that spending remains aligned with its growth strategy.

Clinical and KOL Validation

The company pointed to a Delphi expert consensus that positions DAYBUE as the standard of care for Rett syndrome, a key endorsement from clinical leaders. Management said this validation is helping drive broader adoption across centers of excellence and underpins confidence in sustaining DAYBUE’s commercial ramp.

Q1 NUPLAZID Refill Timing Disruption

A temporary shift in refill behavior among NUPLAZID patients in January and early February weighed on reported Q1 revenue as some patients took longer to refill their prescriptions. Executives stressed that these late refills represent a timing issue and not patient losses, noting that many patients returned later in the quarter even though the delay reduced revenue recognized in the period.

Significant SG&A Expense Increase

Selling, general and administrative expenses surged to $171 million in Q1 2026 from $126.4 million a year earlier, a jump of about 35.3% tied to commercial build‑out and sales force expansion. While this meaningfully raises near‑term operating spend, management framed the investments as necessary to support long‑term revenue growth from NUPLAZID and DAYBUE.

High Gross-to-Net Adjustments

Investors were reminded that gross‑to‑net deductions remain substantial, with NUPLAZID adjustments at 22.1% and DAYBUE at 25.8% during the quarter. These discounts and rebates materially reduce reported net product revenue, highlighting the importance of monitoring reimbursement dynamics in assessing the sustainability of ACADIA’s top‑line growth.

Regulatory Uncertainty in Europe for Trofinetide

The company acknowledged ongoing regulatory risk in Europe for trofinetide, where a reexamination process remains in progress following a prior negative opinion. Management expects the process to conclude by late June but emphasized that the outcome remains uncertain, underscoring the importance of engagement with European regulators for this asset.

R&D Leadership Transition Risk

ACADIA disclosed that its head of R&D will retire at year‑end, though the executive will stay involved through key upcoming data readouts to support continuity. The company outlined transition plans but conceded that leadership changes introduce some execution risk as it advances multiple late‑stage programs toward pivotal milestones.

Early STIX Sample Size and Transparency Change

While initial STIX uptake metrics appear strong, management noted that current data are based on a relatively small base of roughly 250 prescriptions and a focused launch through centers of excellence. The company also said it will no longer disclose patient shipment counts for STIX going forward, a shift that trims a layer of operational transparency for investors tracking the launch.

Forward-Looking Guidance and Outlook

Looking ahead, ACADIA reiterated its full‑year 2026 revenue guidance of $1.22 billion to $1.28 billion and said results will be weighted toward the second half as the expanded NUPLAZID field force ramps and DAYBUE STIX becomes more widely available. Management reaffirmed longer‑term goals of about $1 billion in NUPLAZID sales and roughly $700 million in DAYBUE sales by 2028, while targeting five additional Phase II/III trial initiations and four key readouts by the end of 2027.

ACADIA’s earnings call painted a picture of a company leaning into growth, with solid revenue momentum, validated products and a pipeline brimming with catalysts. Against that backdrop, higher near‑term spending, European regulatory uncertainty and leadership changes are key risks to watch, but management’s reaffirmed guidance and strong cash balance suggest confidence in the path it has laid out for investors.